The Crohn’s disease (CD) therapy market is expected to see increasing use of biologics and grow steadily over the next decade. The well-established TNF-α inhibitors (e.g., Janssen/Merck’s Remicade, AbbVie / Eisai’s Humira), together with newer therapies (i.e., Takeda’s Entyvio, a CAM inhibitor, and Janssen’s Stelara, an IL-12/23 inhibitor), have transformed the treatment landscape for CD, especially for moderate to severe disease, despite these drugs’ efficacy limitations (e.g., patients lose response over time) and safety risks. The impending entry of several new therapies offering more-convenient formulations and/or novel mechanisms of action (e.g., Galapagos / Gilead’s filgotinib, TiGenix / Takeda’s Alofisel, AbbVie’s risankizumab and upadacitinib, Celgene’s ozanimod) will further improve treatment and intensify market competition. In balance with these trends, the continuing generic erosion of conventional agents and the availability of less-expensive biosimilar TNF-alpha inhibitors will constrain CD therapy sales.


  • What are KOLs’ opinions of current treatment options (e.g., Remicade, Humira, Stelara, Entyvio)? How have biosimilars influenced treatment practices? What factors drive treatment decisions?
  • What do KOLs think about emerging therapies (e.g., filgotinib, risankizumab, upadacitinib, ozanimod)? What impact will stem-cell therapy and oral therapies have on the CD treatment algorithm?
  • Which emerging agents are likely to be most successful in targeting TNF-refractory patients and gaining uptake in the CD market?
  • How will the market evolve over the next ten years?


Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Table of contents

  • Disease Landscape & Forecast
    • COVID-19
    • Key Findings
    • Key Updates
      • June 2020
      • November 2019
      • September 2019
      • June 2019
    • Market Outlook
      • COVID-19: Areas of Potential Forecast Impact
      • Key Findings
      • Market Drivers and Constraints
        • What Factors Are Driving the Market for Crohn's Disease?
        • What Factors Are Constraining the Market for Crohn's Disease?
      • Drug-Class-Specific Trends
        • TNF-Alpha Inhibitors
        • IL-12/IL-23 Inhibitors
        • CAM Inhibitors
        • IL-23 Inhibitors
        • JAK Inhibitors
        • Stem-Cell Therapies
        • S1P Receptor Modulators
        • Oral Aminosalicylates
        • Immunosuppressants
        • Corticosteroids
    • Forecast
      • Market Forecast Assumptions
      • Market Forecast Dashboard
    • Etiology and Pathophysiology
      • Disease Overview
      • Etiology and Pathophysiology
        • Overview
        • Genetic Influence
        • Microbial Involvement
        • Environmental Factors
        • Mucosal Immune Response
        • Chronic Inflammation
      • Key Pathways and Drug Targets
    • Epidemiology
      • Key Findings
      • Epidemiology Populations
        • Diagnosed Prevalent Cases of Crohn's Disease
        • Diagnosed Prevalent Cases of Crohn's Disease by Disease Activity
        • Diagnosed Cases of Crohn's Disease
        • Drug-Treated Cases of Crohn's Disease
    • Current Treatment
      • Key Findings
      • Treatment Goals
      • Key Current Therapies
        • Overview
        • TNF-Alpha Inhibitors
        • CAM Inhibitors
        • IL-12/23 Inhibitors
        • Aminosalicylates
        • Immunosuppressants
        • Corticosteroids
        • Antibiotics
      • Medical Practice
        • Overview
        • Region-Specific Treatment Practices
    • Unmet Need Overview
      • Current and Future Attainment of Unmet Needs in Crohn's Disease
      • Introduction
        • Key Findings
        • Expert Insight
      • Attainment of Unmet Needs
        • Future Attainment of Unmet Needs in Crohn's Disease
        • Current Attainment of Unmet Needs in Crohn's Disease
    • Emerging Therapies
      • Key Findings
      • Key Emerging Therapies
        • Interleukin-23 Inhibitors
        • Stem-Cell Therapies
        • CAM Inhibitors
        • JAK Inhibitors
        • Sphingosine-1-Phosphate Receptor Modulators
      • Early-Phase Pipeline Analysis
      • Key Discontinuations and Failures in Crohn's Disease
    • Access and Reimbursement Overview
      • Region-Specific Reimbursement Practices
        • United States
        • EU5
        • Japan
    • Methodology
      • Bottom-Up Forecasting Overview
        • Patient Populations
        • Drug-Specific Assumptions
      • Bottom-Up Forecast Assumptions
        • General Sources of Data
        • Agents Included in Our Market Analysis
        • General Statements About Pricing
        • Dosing, Days of Therapy, and Compliance
        • Generic Erosion
        • Biosimilar Erosion
        • Out-Year Forecasting
        • Emerging Therapy Prices
      • Primary Market Research
        • Experts Interviewed
    • Appendix
      • Crohn's Disease Bibliography

Author(s): Ritesh Gupta, PhD; Abey John, MPH

Ritesh Gupta is a Lead Analyst on the immune and inflammatory disorders team at Decision Resources Group, whose work focuses primarily on Psoriatic Arthritis, Ulcerative Colitis and Crohn’s Disease. He holds a degree in Cell Biology from Max Delbrück Center for Molecular Medicine, Berlin, where he worked on development of novel inhibitors for HGF/MET signaling pathways. Prior to joining DRG, Ritesh has worked as an assistant manager with BioXcel corporation and provided insights on various consulting projects. He was also associated with GVK Biosciences and worked on drug repurposing projects.

Abey John is a medical graduate with a Master’s in Public Health and has been associated with DRG since September 2015. He works with a global team of epidemiologists in performing systematic reviews of assigned diseases and prepare forecast models for clients. He also is involved in producing analyses for pharmaceutical drug developers on the descriptive epidemiology of major drug indications in mature and developing markets and have an overall experience of three years working in different healthcare sectors across the country. Prior to joining DRG, Abey had been working with Jhpiego (an affiliate of Johns Hopkins Medical University) in implementing Family Planning Health Programs in India with collaborating with the Government of India. He also has worked with a grassroots level NGO as a health team manager which worked for the benefit of the rural population living in the foothills of the Himalayas.

Related Reports

Crohn's Disease | Current Treatment | Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis (US) - Pediatric

Children with Crohn’s disease (CD) have a more-complicated disease course compared with adult patients. However, similar to adult

View Details

Crohn's Disease | Unmet Need | Detailed, Expanded Analysis (US & EU)

TNF-alpha inhibitors (e.g., Janssen’s Remicade, AbbVie’s Humira) are the mainstay of biological treatment for moderate to severe Crohn&rsquo...

View Details

Crohn's Disease | Current Treatment | Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis (US) - Adult

Crohn’s disease (CD) is a chronic inflammatory disorder of the gastrointestinal tract characterized by diarrhea, abdominal pain, and weight loss. The pr...

View Details

Crohn's Disease | Disease Landscape and Forecast | G7 | 2019

The Crohn’s disease (CD) therapy market is expected to see increasing use of biologics and grow steadily over the next decade. The well-established 

View Details